BDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Becton Dickinson and Co (BDX) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock is currently oversold with a strong RSI signal, hedge funds are increasing their positions significantly, and the company has shown solid financial performance in its latest quarter. Despite some short-term technical weakness, the long-term growth potential, positive analyst sentiment, and recent product approvals make this a favorable investment opportunity.
The stock is in a bearish trend with the MACD histogram at -0.858 and negatively expanding, indicating downward momentum. The RSI of 17.787 suggests the stock is oversold, which could present a buying opportunity. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level of 170.213, with further support at 165.604.
Hedge funds are significantly increasing their positions, with a 956.90% increase in buying over the last quarter.
Positive news on product approvals, including the Revello™ vascular stent receiving CE marking and Surgiphor™ 1000mL receiving FDA clearance, which could drive future revenue growth.
Strong financial performance in Q1 2026, with revenue, net income, EPS, and gross margin all showing YoY growth.
The stock is in a bearish technical trend with negative MACD and moving averages.
Analyst price target adjustments include some downgrades, such as RBC Capital lowering the target to $172 and Piper Sandler lowering it to $170, reflecting cautious sentiment.
The market sentiment is slightly negative, with the broader S&P 500 index down 0.56%.
In Q1 2026, Becton Dickinson reported revenue growth of 1.63% YoY to $5.252 billion, net income growth of 26.07% YoY to $382 million, EPS growth of 28.85% YoY to $1.34, and gross margin improvement of 5.13% YoY to 45.91%. This indicates strong operational performance and profitability.
Analysts generally maintain a positive outlook on BDX, with several Buy ratings and price targets ranging from $170 to $233. Citi and Barclays are optimistic about the company's growth potential following the LifeSciences sale, while RBC and Piper Sandler are more cautious, citing the need for mid-single-digit growth recovery.
